Klaria's objective is to combine the Company's patented drug delivery platform with the most relevant and effective substances when it comes to pain relief and other indications where the platform is expected to enable significant advantages, such as treatment of opioid overdose and anaphylactic shock.

Objective in 2017-2018 is to complete the formulations in all projects and to start testing priority projects in clinical trials.